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Introduction: Several neurodegenerative diseases are classified as proteopathies as they are associated with the
aggregation of misfolded proteins. Synucleinopathies are a group of neurodegenerative disorders associated with
abnormal deposition of synucleins. α-Synucleinopathies include Parkinson’s disease, dementia with Lewy bodies,
and multiple system atrophy. Recently accumulation of another member of the synuclein family- γ−synuclein in
neurodegenerative diseases compelled the introduction of the term γ−synucleinopathy. The formation of aggregates
and deposits of γ−synuclein is facilitated after its oxidation at methionine 38 (Met38).
Results: Several types of intracytoplasmic inclusions containing post-translationally modified α- and γ−synucleins are
detected. Oxidized Met38-γ-synuclein forms aberrant inclusions in amygdala and substantia nigra. Double staining
revealed colocalization of oxidized-γ-synuclein with α-synuclein in the cytoplasm of neurons. Another type of synuclein
positive inclusions in the amygdala of dementia with Lewy bodies patients has the appearance of Lewy bodies.
These inclusions are immunoreactive when analyzed with antibodies to α-synuclein phosphorylated on serine
129, as well as with antibodies to oxidized-γ-synuclein. Some of these Lewy bodies have doughnut-like shape
with round or elongated shape. The separate immunofluorescent images obtained with individual antibodies
specific to oxidized-γ-synuclein and phospho-α-synuclein clearly shows the colocalization of these synuclein isoforms
in substantia nigra inclusions. Phospho-α-synuclein is present almost exclusively at the periphery of these structures,
whereas oxidized-γ-syn immunoreactivity is also located in the internal parts forming dot-like pattern of staining.
We also identified several types of oxidized-γ-syn positive astrocytes with different morphology and examined
their immunohistochemical phenotypes. Some of them are compact cells with short processes, others have longer
processes. Oxidized-γ-synuclein positive astrocytes may also display mixed morphological and immunocytochemical
phenotypes between protoplasmic and fibrous astrocytes.
Conclusions: These results reveal new γ−synuclein positive lesions in human brain. Oxidized-γ-synuclein is colocalized
with phospho-α-synuclein in doughnut-like inclusions. Several types of astrocytes with different morphology are
immunopositive for oxidized-γ-synuclein.
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The pathophysiological changes associated with neuro-
degenerative diseases (NDDs) begin decades before the
emergence of clinical symptoms. Understanding the early
mechanisms associated with NDDs pathology is, therefore,
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article, unless otherwise stated.targets. Recent genetic and biochemical analysis has
confirmed that the abnormal accumulation of naturally
unfolded proteins in the brain is central to several NDDs.
These “cerebral proteopathies” include dementia with
Lewy bodies (DLB), Alzheimer’s disease (AD), Parkinson’s
disease (PD) and a variety of other disorders. AD, the
most common form of dementia, is characterized by
accumulation of intraneuronal deposition of the hyper-
phosphorylated tau protein (neurofibrillary tangles) and
extracellular aggregates of β-amyloid (amyloid plaques).
However, amyloid accumulation often also occurs in
patients with DLB and in some patients with PD withntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cases exhibit abundant brain accumulation of α-synuclein
(α-syn) positive Lewy bodies (LBs) [2,3]. On the other
hand, α-syn accumulates in PD and is considered as a
potential biomarker of this disorder.
α-Syn (α-syn) is ubiquitously expressed in brain and is
highly enriched in presynaptic nerve terminals, where its
main physiological function is the regulation of synaptic
levels of monoamine neurotransmitters through modula-
tion of vesicular release. The results of analysis of total
α-syn in peripheral blood, plasma and cerebrospinal fluid
(CSF) do not confirm that it can be used as a reliable
biomarker or predictor of disease progression. However,
post-translationally modified forms of α-syn and in par-
ticular Ser129 phosphorylated isoform (phospho-α-syn) [4]
might have potential value as a diagnostic tool [5,6].
Quantification of post-translationally modified forms
of these proteins elicits more hope to find a new bio-
marker useful for diagnostic purposes. The finding and
characterization of dependable novel biomarkers is still
highly unmet and much needed. Initial findings of new
biomarkers using post-mortem brain samples may lead
to their subsequent testing with biological fluids, i.e.
serum or cerebrospinal fluid and become a basis for the
development of new diagnostic tools.
Another member of the synuclein family - γ-synuclein
(γ-syn) is also aggregation-prone protein which forms
intracellular inclusions. γ-Syn is a component of atypical
inclusion bodies in human NDDs [7-11]. Furthermore,
elevated expression of γ-syn causes selective damage and
loss of discrete populations of neurons and their axons
[9,12]. Importantly, polymorphisms in the γ-syn locus have
been associated with human diffuse Lewy body disease
[13]. Formation of heteromeric complexes containing
α- and γ-syn was demonstrated [14]. Our recent results
indicate that γ-syn is easily oxidized at Methionine-38
(Met-38) forming oxidized-γ-syn (oxi-γ-syn) and after
oxidation it can induce aggregation of α-syn [15]. More-
over, γ-syn can be transmitted between cells [15] and
presumably to spread pathology as was shown for α-syn
[16-18]. These findings raise a possibility that oxidation
and/or aggregation of this protein might be involved in
the pathogenesis of some NDDs. This prompted us to
investigate if γ-syn pathology is present in patients with
AD with LB, DLB and PD.
Naturally unfolded proteins, including synucleins, are
often post-translationally modified which may serve as a
signal for their sequestration in inclusion bodies [4,19,20].
Previously we have found that γ-syn can be easily oxidized
and form aggregates and inclusions in cell cultures
[15]. Here we used antibodies specific to unmodified and
post-translationally modified α- and γ-syns to reveal
immunopathology in brain tissues of patients with NDDs.
In particular, we used antibodies to pSer129-α-syn, α-synspecific antibody raised against LB and antibody to
oxi-Met38-γ-syn. We also identified several types of
oxi-γ-syn positive astrocytes with different morphology
and examined their immunohistochemical phenotypes.
Finding of new astrocytes markers which could distinguish
different types of astrocytes is important for better under-
standing of their role in healthy brain and in NDDs.
Materials and methods
Brain specimens of the amygdala and the substantia
nigra were obtained from the brain bank of the University
of Kansas Medical Center Alzheimer’s Disease Center.
Tissue was requested from pathologically-defined cases
with the presence of Lewy bodies and included individuals
with AD-related changes, PD, and DLB. A primary diag-
nosis was defined based on the burden of pathology and
neuropathological characteristics.
Paraffin sections were used to retrieve two formalin-
fixed, paraffin-embedded blocks, one for the amygdala
and the other for the substantia nigra. From each of these
paraffin blocks, 7 μm sections were cut and mounted on
microscope slides. The formalin-fixed paraffin-embedded
brain sections were deparaffinized by standard method.
Heat-mediated antigen retrieval procedure using 10 mM
sodium citrate buffer, pH-6.0 was applied. Permeabi-
lization was done in PBS containing 0.2% Triton X-100
for 45 min at RT. Blocking was carried out overnight
at +4°C in 10% normal horse serum containing 0.05%
Triton-X-100.
Antibodies
For immunofluorescent staining the following primary
antibodies were used.
Primary antibodies
Polyclonal antirabbit antibody to oxi-γ-syn was gener-
ated as described in our previous publication [15], α-syn
antibody (ab6162 from Abcam, San Francisco, CA) was
generated to human synthetic peptide in sheep, pSer129-
α-syn from Wako (Richmond, VA), monoclonal antimouse
GFAP (Mab360, Millipore, Temecula, CA), polyclonal anti-
goat - Iba1 - (Cat. #ab 107159, Abcam, San Francisco,
CA) have been used for immunofluorescent staining.
The following monoclonal antibodies have been also
applied: antimouse β-amyloid (clone 6E10, Covance,
Princeton, NJ) and antimouse γ-syn antibody (clone
1H10D2, Antagene, Mountain View, CA). Antibodies to
the following astrocytes markers have been used: mono-
clonal anti-Aldh1L1, clone N103/39 (Cat #MABN495,
NeuroMab UC, Davis, CA) is used as a protoplasmic
astrocytes marker. Monoclonal mouse antihuman CD44,
phagocytic glycoprotein-1 (Clone F10-44-2, Dako, Carpen-
taria, CA) was used to identify CD44+ astrocytes. Mouse
anti-glutamine synthetase (Cat# 610517, BD Transduction
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cyte marker.
Secondary antibodies
The following secondary antibodies were used. Donkey
antisheep- IgG-TR (Cat# sc-3913, Santa Cruz, Dallas,
Texas), Alexa Fluor 594-goat antimouse, Alexa Fluor
594-donkey antigoat, Alexa Fluor 488 – donkey antirab-
bit were from Jackson ImmunoResearch Lab (West
Grove, PA). Incubation with secondary antibodies was
carried out for 2 h at RT in the dark. Autofluorescence
Eliminator Reagent (Millipore, Temecula, CA) was applied
to reduce autofluorescence. Finally, the slides were cov-
ered by Vectashield –mounting medium containing DAPI
(Vector Labs, Burlingame, CA). The images were received
using a Nikon 80i Upright scope supplied with the
digital camera Olympus DP72 (Center Valley, PA) and
the software Olympus Cell Sense.
Immunofluorescence staining
Was performed on 8 μm thick frozen sections. The
sections were fixed in 2% paraformaldehyde for 10 min,
washed and then permeabilized in 0.2% Triton X-100 in
PBS for 1 h. The slides were blocked with 10% normal
horse serum in PBS + 0.05% Triton X-100 and then theFigure 1 Specificity of synuclein antibody toward recombinant protei
α-syn (lanes 1 and 6), γ-syn (lanes 2 and 7) and γ-syn treated with DA (oxi-γ-sy
SDSNa and tested with antibodies specific to different synucleins isoforms. Th
2 and 7 – untreated -γ-syn - 62.5 ng. Since in the course of the treatment b
reduced, we applied increasing amounts of proteins: 100 ng on lanes 3 and
probed with antibodies against oxi-γ- syn (lanes 1–5) and antisheep-α-synu
recognizes monomeric form of γ-syn (lane 1), while antibody to oxi-γ-syn re
γ-syn (lane 2) and in extracts of human brain (3–6). Lanes 3 and 5 extracts fr
nigra from control individuals.primary antibodies were added at a dilution 1:100 for
overnight incubation at 4°C in 5% normal horse serum
in PBS + 0.05% Triton X-100. The following day the
slides were washed 3 times (PBS + 0.05% Triton X-100),
15 min each and incubated with secondary fluorescent
antibodies (Alexa Fluor conjugates) at 1:500 dilution and
Donkey anti-sheep Texas red at 1:250 dilution for 2 h at
RT followed by washing as described above. Then the
slides were mounted in VectaShield with DAPI (Vector
Laboratories, Burlingame CA). The slides were imaged
using an Olympus BX46 fluorescent microscope at
40× magnification.
Immunochemistry
The slides were treated as described above with the
following modifications. After blocking the sections were
incubated with polyclonal oxi-γ-syn antibody (dilution
1:100) overnight at 4°C. Unbound antibody was removed
by washing in PBS and the incubation with rabbit HRP
conjugated sustained for 1 h at RT. Then Vectastatin kit
was used (Vector Laboratories, Burlingame, CA) and the
staining was visualized by precipitation of Diaminoben-
zidine (DAB) (Sigma Aldrich, St. Louis, MO) following
the manufacturer’s instructions. In negative controls the
primary antibodies were omitted.ns (A) and extracts from cell culture and brain (B). A: Recombinant
n, lanes 3–5 and 8–10) were separated in 12% polyacrylamide gel with
e following amounts of protein were subjected to electrophoresis: lanes
y 250 μM DA the amount of immunoreactive monomeric γ-syn was
8; 187.5 ng on lanes 4 and 9; and 225 ng on lanes 5 and 10. WB was
clein (lanes 6–10). B: Antibody to unmodified γ-syn (ABcam, 55424)
cognizes tetrameric γ-syn in cell extracts of SH-SY5Y cells overexpressing
om amygdala were analyzed; lanes 4 and 6 – extracts from substantia
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For calculation of oxi-γ-syn positive astrocytes we used
7 amygdala and 7 substantia nigra slices for each case.
After staining we calculated the number of oxi-γ-syn
astrocytes present on the whole slices.
Western blotting
The brain extracts (30 μg total protein) were analyzed by
WB in a 12% polyacrylamide gel (PAAG) in the presence of
SDS as described previously [10,15]. After electrophoresis,
proteins were transferred onto an Immobilon-FL transfer
membrane (0.45 μm, Millipore, Chelmsford, MA). Non-
specific binding sites were blocked by immersing the
membrane in PBS with 5% nonfat dry milk for 1 h at
room temperature (RT) on an orbital shaker. For quan-
titative imaging of bands an infrared imaging system
(Odyssey, LiCor, Lincoln, NE) was used. Other details
have been described previously [15].
Results
Since we used home-made antibody to oxi-γ − syn we
first tested its specificity using recombinant proteins,Figure 2 Colocalization of α-syn with oxi-γ-syn in amygdala and subs
paraffin-embedded sections (bottom row) of substantia nigra and amygdala o
sections (A and B) were stained using H&R- DAB –procedure and oxi-γ-syn a
nigra from S3 patient (AD with LB), C- the same as in A, but without primary
patient were stained by oxi-γ-syn antibody; D - α-syn antibody (Abcam ab616
The bottom row. The sections were double stained with antibody against α-s
homemade antibody). Yellow cytoplasmic staining is shown by an arrow in a
amygdala taken from a patient S4 with AD with LB (H) substantia nigra from
γ-syn (clone 1H10D2, Antagene) (red) reveals a weak staining of unmodified γextracts from cultured cells and brain extracts. Oxi-γ-syn
was prepared by incubation of recombinant protein with
250 μM dopamine (DA) as described previously [15]
(marked “treated γ“ on Figure 1, lanes 3–5 and 8–10).
Antibody to oxi-γ-syn does not cross react with α-syn
(Figure 1A, lane 1) and antibody to α-syn does not cross
react with γ-syn (Figure 1A, lanes 7–10). Both these
antibodies recognize only corresponding monomeric
recombinant protein with molecular weight ~14 KDa
(lane 2 for γ − syn and lane 6 for α-syn). However, when
used with extracts from cultured cells (Figure 1B, lane 2)
or brain extracts (lanes 3–6) antibody to oxi-γ-syn
recognizes tetrameric form of γ-syn (~55 Kda, arrow
on Figure 1B). In addition to tetramers lower molecular
weight bands are present in brain extracts which are
presumably products of the tetramer degradation (arrow-
head, lanes 3–6, Figure 1B).
Then we investigated synuclein localization in brain
samples from patients and controls using antibodies to
several synuclein isoforms. Accumulation of aberrant
oxi-γ-syn in frozen sections of substantia nigra was
revealed by H@R – DAB procedure in neurites (Figure 2A,tantia nigra in AD with LB patients. Frozen (two top rows) and
f healthy (A, G) and AD patients with DLB (H, I). The top row: frozen
ntibody. A- substantia nigra from K46 healthy individual, B - substantia
antibody. In the middle row the sections of substantia nigra from S3
2, antisheep); E - oxi-γ-syn antibody; F - colocalization of both antibodies.
yn (red, Abcam ab 6162, antisheep) and oxi-γ-syn (green, antirabbit,
sample from amygdala of K21-healthy donor (G) and in a sample from
patient S3 suffering from mild AD with LB (I). Antibody to unmodified
-syn in the cytoplasm of neurons.
Figure 3 The presence of post-translationally modified α- and γ-syn in LB. The immunofluorescence staining of sections by individual
antibody. A-C - substantia nigra of S3 patient (AD with LB). A - oxi-γ-syn immunoreactivity, B- phospho-α-syn immunoreactivity, C- merged. D-F -LB
from amygdala of a patient K33 with DLB. D - oxi-γ-syn immunoreactivity, E- phospho-α-syn immunoreactivity, F – merged. Blue - DAPI staining.
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patient, case S3). Since oxi-γ-syn may initiate α-syn
aggregation [15] we examined whether these synuclein
isoforms have overlapping intracellular localization. α-
Syn (D) and oxi-γ-syn (E) are present in overlapping
cytoplasmic localization (a merged image F) in frozen
sections of substantia nigra. A similar overlappingFigure 4 Oxi-γ-syn positive cells with long processes are identified as
synthetase (D- F). GS-positive astrocytes have relatively long branched pro
GFAP-positive astrocytes (A).cytoplasmic localization was observed when formalin–
fixed paraffin-embedded slices were used for double
staining (G-I). Oxi-γ-syn positive cells were identified as
neurons with neuronal marker MAP2 (not shown).
Intracytoplasmic inclusions with appearance of LB were
detected in the amygdala of DLB patients immunoreactive
with an antibody specific to phosphorylated on Ser129 α-astrocytes with specific markers, GFAP (A-C) and glutamine
cesses (D) compared to more compact bushy-like spherical
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of these structures have doughnut-like shape with round
(A- C) or elongated (D-F) morphology; they are identified
in substantia nigra by double staining with an antibody
specific to phosphorylated Ser129 α-syn (B, E) and anti-
body to oxi-γ-syn (A,D). Colocalization of phospho-α-syn
(red) and oxi-γ-syn (green) in LB-like structures is shown
in Figure 3C and F. In these structures α-syn staining is
present almost exclusively as peripheral ring-like pattern
(Figure 3B), whereas oxi-γ-syn immunoreactivity is also
located in the internal parts forming dot-like pattern of
staining (Figure 3A).
In addition to the presence in lesions described above
oxi-γ-syn is localized in several types of astrocytes,
which are identified by colocalization with astrocyte
markers GFAP (Figure 4, A, C) and glutamine synthetase
(D and F). A partial colocalization of oxi-γ-syn immu-
noreactivity with other astrocyte markers, Aldh1L1
(Figure 5A, C) and CD44 (D, F) is shown on Figure 5.
Oxi-γ-syn-positive astrocytes are phenotypically heteroge-
neous, having different shape and length of their processesFigure 5 Oxi-γ-syn positive astrocytes have a partial colocalization wi
not colocalized with an oligodendrocyte marker CNPase (I). A, D, G –
oxi-γ-syn-positive astrocytes reside near large blood vessels (V, C and F) w(Figures 4 and 5, green staining). They are identified
as astrocytes using GFAP antibody (Figure 4, C) and
glutamine synthetase (GS) antibody (Figure 4, F). GS-
positive astrocytes have relatively long branched processes
(Figure 4, D-F) compared to more compact bushy-like
GFAP-positive astrocytes (Figure 4, A, C). Some types of
oxi-γ-syn positive astrocytes have a partial overlap with
such astrocytes markers, as Aldh1L1 (Figure 5C) and
CD44 (Figure 5, F), while there is no overlap with an
oligodendrocyte marker CNPase (Figure 5I). Some of oxi-
γ-syn-positive astrocytes reside near large blood vessels
(V) (Figure 5C and F) with processes extending toward
the vessel surface (Figure 5C). The number of oxi-γ-syn–
positive astrocytes is the highest in PD patients and differs
significantly in patients and controls (Table 1).
Discussion
PTMs have emerged as important determinants of pro-
tein physiological and pathological functions. Several
PTMs are enriched within LB and exist at higher levels
in α-synucleinopathy brains. Synuclein’s PTMs interfereth astrocyte markers Aldh1L1 (C) and CD44 (F) (arrows) and are
oxi-γ-syn staining. B – Aldh1L1, E- CD44, H –CNPase staining. Some of
ith processes extending toward the vessel surface (C).
Surgucheva et al. Acta Neuropathologica Communications 2014, 2:132 Page 7 of 9
http://www.actaneurocomms.org/content/2/1/132with its aggregation propensity and cellular signaling
[19-22]. These findings suggest that PTMs of synucleins
may signal a shift to a toxic gain of function and/or
sequestration into insoluble structures. Here we have
shown that phospho-α-syn and oxi-γ-syn are colocalized
in LB in amygdala and substantia nigra of DLB, PD and
some AD patients. The results of Western blotting show
the absence of cross reactivity between antibodies we
used for identification of α- and γ-syn. We also revealed
another type of γ-syn immunopositive staining of astrocytes
which are present both in DLB patients and in control
brain samples. The presence of oxi-γ-syn in intracellular
deposits may have an important role in the process of
inclusion formation, since oxi-γ-syn induces protein
aggregation [15] and thus may initiate protein deposition.
Interestingly, intracellular inclusions similar to doughnut-
like LB shown on Figure 2B-D have been described
recently in DLB patients using antibodies to α-syn and
caspase-cleaved TDP-43 [23]. Both markers are uniformly
distributed in these structures in PD cases, but peripher-
ally distributed in patients with DLB.
In contrast to formation of synuclein inclusions in
neurons, we did not find similar inclusions and deposits
in astrocytes, although glial accumulation of α-syn was
described previously, especially at the step of initiation
of NDDs [24,25]. The role of neuron-glia interaction in
the etiology of NDDs is an important area of currentTable 1 The amount of oxi- Met3 - γ-synuclein –positive
astrocytes in patients with NDDs and control individuals
Patient’s ID Sex Age Diagnosis Number of oxi-Met38 -γ-
syn–positive astrocytes
K33 M 76 DLB +
K11 F 87 AD with DLB related
pathology
+
K13 M 85 DLB ++
K39 M 74 DLB +
S3 M 73 DLB +mild AD +++
S4 F 87 AD with DLB related
pathology
++
PD1 M 55 PD ++
PD2 M 85 PD ++++
K21 M 97 Control ++
K35 F 61 Control +
K41 F 61 Control ++
K45 M 66 Control +
K46 M 79 Control +++
K48 F 88 Control +++
The patients were selected based on the neuropathological characteristics. The
number of oxi-Met38 –positive astrocytes was calculated on a 2 x 2.5 cm slice.
+ represents the number of oxi-Met38 –positive astrocytes from 1 to 2.
++ represent the number of oxi-Met38 –positive astrocytes from 2 to 5.
+++ represent the number of oxi-Met38 –positive astrocytes from 5 to10.
++++ represent the number of oxi-Met38 –positive astrocytes > 10.investigations due to the involvement of naturally unfolded
proteins in prion-like transmission of pathology [16-18,24].
The results presented here are in agreement with previous
observations of aberrant γ-syn accumulation in the optic
nerve astrocytes and spheroids which is not accompanied
by the formation of inclusion bodies or deposits [10,11]
We identified several types of oxi-γ-syn positive
astrocytes with different morphology and examined their
immunohistochemical phenotypes. Some of them are
compact with short processes (Figure 4A and D) looking
similar to protoplasmic astrocytes [26,27], others have
longer processes (Figure 4D and G) which may end on a
blood vessel (Figure 5C). Some of the oxi-γ-syn positive
astrocytes display mixed morphological and immuno-
cytochemical phenotypes between protoplasmic and fibrous
astrocytes (Figure 4A and C). The quantity of oxi-γ-syn
positive astrocytes differs significantly in patients with
different NDDs and controls. They are most frequent in
patients with PD (Table 1). Astrocytic α-syn is considered
an important component of the pathology [28,29], however
the role of γ-syn and post-translationally modified forms
of synucleins in neurodegeneration is not completely
understood.
The results presented here might be important for
better understanding of mechanisms initiating the
formation of protein deposits in NDDs. Findings from
several recent studies have suggested that aggregation-
prone proteins, such as tau, α-syn, polyglutamine-
containing proteins, and amyloid-β, can enhance each
other’s aggregation [30-35]. In particular, β-amyloid
augments α-syn accumulation [33,34], Tau increases
α-syn aggregation [31,32] while synergistic interactions
between β-amyloid, tau, and α-syn might accelerate
neuropathology [33]. Importantly, mechanism of hybrid
oligomer formation plays an essential role in the patho-
genesis of combined AD and PD [30].
A role of γ-syn and its post-translationally modified
forms in NDDs are not investigated in such details as of
α-syn and other naturally unfolded proteins. However,
neuronal accumulation of aberrant γ-syn in NDDs sug-
gests that γ-syn plays an important, yet not completely
understood role in these disorders. Furthermore, its
presence in cerebrospinal fluid and elevation in aged
subjects with neurodegenerative and vascular changes
suggest that γ-syn can be used as a biomarker of neuro-
degeneration, gliosis in dementia with Lewy bodies and
other NDDs [36].
Recent studies have demonstrated that α- and γ-syn
interact with each other and these interactions increase
the propensity of synucleins to aggregate [15,37]. Co-
immunoprecipitation experiments showed heteromeric
protein: protein complexes that included both α- and
γ-syns [14,15]. Thus, antibody to oxi-γ-syn can be used
as a new biomarker for NDDs both individually and in
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generation. The presence of both α-syn and γ-syn in
brain deposits in several NDDs may suggest a common
element in the mechanism leading to these disorders.
Astrocytes exert many essential and complex functions
and react to all forms of CNS insults, including NDDs
with a response referred to as reactive astrogliosis. Find-
ing of new astrocytes markers which could differentiate
various types of astrocytes is important for better under-
standing of their role in healthy brain and in NDDs.
Conclusions
The results presented here confirm previous findings that
accumulation of γ-syn may occur in human brain. Lesions
immunopositive for both α-syn and γ-syn, as well oxi-γ-
syn positive astrocytes with different morphology are
described.
Abbreviations
AD: Alzheimer’s disease; DLB: Dementia with Lewy body; LB: Lewy body;
NDDs: Neurodegenerative diseases; PD: Parkinson’s disease; Phospho-α-
syn: Phosphorylated at Ser-129 α-synuclein; Oxi-γ-syn: Oxidized at Met-38
γ-synuclein.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: IS AS KLN.Performed the
experiments: IS. Analyzed the data: IS, JB, AS, KLN. Contributed reagents/
materials/analysis tools: IS, KLN, AS. Wrote the paper: AS, JB, KLN, IS. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by VA Merit review grant and the Glaucoma
Foundation grant. We are grateful to professor Ben. Barres (Stanford
University) and Alexander Sosunov (Columbia University, NY) for many
helpful discussions. We are thankful to Cynthia Gouvion from the Pathology
and Laboratory Medicine Department of KUMC for help with brain samples.
Kelly L. Hudkins (Department of Pathology, University of Washington, Seattle)
help with immuno-histochemical staining is greatly appreciated. The funders
had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Author details
1Retinal Biology Research Laboratory, VA Medical Center, 4801 East Linwood
boulevard, 64128 Kansas City, MO, USA. 2Department of Neurology, Kansas
University Medical Center, 3901 Rainbow Boulevard, 66160 Kansas City, KS,
USA. 3Alzheimer’s Disease Center, Department of Neurology, Kansas University
Medical Center, 3901 Rainbow Boulevard, 66160 Kansas City, KS, USA.
Received: 15 July 2014 Accepted: 20 August 2014
References
1. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL,
O’Keefe G, Någren K, Chaudhury KR, Masters CL, Brooks DJ: Amyloid load in
Parkinson’s disease dementia and Lewy body dementia measured with
[11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry
2008, 79(12):1331–1338.
2. Resende R, Marques SC, Ferreiro E, Simões I, Oliveira CR, Pereira CM: Effect
of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body
variant of Alzheimer disease. Neurochem Res 2013, 38(4):797–806.
3. Hamilton RL: Lewy bodies in Alzheimer’s disease: a neuropathological
review of 145 cases using alpha-synuclein immunohistochemistry.
Brain Pathol 2000, 10:378–384.4. Pronin AN, Morris AJ, Surguchov A, Benovic JL: Synucleins are a novel class
of substrates for G protein-coupled receptor kinases. J Biol Chem 2000,
275(34):26515–26522.
5. Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, Hasegawa M,
Taylor M, Mann D, Allsop D: Phosphorylated α-synuclein can be detected
in blood plasma and is potentially a useful biomarker for Parkinson’s
disease. FASEB J 2011, 25(12):4127–4137.
6. Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake
M, Mann DM, Allsop D: A longitudinal study on α-synuclein in blood
plasma as a biomarker for Parkinson’s disease. Sci Rep 2013, 3:2540.
7. Galvin JE, Uryu K, Lee VM, Trojanowski JQ: Axon pathology in Parkinson’s
disease and Lewy body dementia hippocampus contains alpha-, beta-, and
gamma-synuclein. Proc Natl Acad Sci U S A 1999, 96:13450–13455.
8. Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ: Neurodegeneration
with brain iron accumulation, type 1 is characterized by alpha-, beta-,
and gamma-synuclein neuropathology. Am J Pathol 2000, 157:361–368.
9. Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL:
Gamma-synucleinopathy: neurodegeneration associated with
overexpression of the mouse protein. Hum Mol Genet 2009, 18(10):1779–1794.
10. Surgucheva I, McMahan B, Ahmed F, Tomarev S, Wax MB, Surguchov A:
Synucleins in glaucoma: implication of gamma-synuclein in glaucomatous
alterations in the optic nerve. J Neurosci Res 2002, 68:97–106.
11. Nguyen JV, Soto I, Kim KY, Bushong EA, Oglesby E, Valiente-Soriano FJ, Yang
Z, Davis CH, Bedont JL, Son JL, Wei JO, Buchman VL, Zack DJ, Vidal-Sanz M,
Ellisman MH, Marsh-Armstrong N: Myelination transition zone astrocytes
are constitutively phagocytic and have synuclein dependent reactivity in
glaucoma. Proc Nat. Acad Sci U S A 2011, 108:1176–1181.
12. Peters OM, Millership S, Shelkovnikova TA, Soto I, Keeling L, Hann A,
Marsh-Armstrong N, Buchman VL, Ninkina N: Selective pattern of motor
system damage in gamma-synuclein transgenic mice mirrors the respective
pathology in amyotrophic lateral sclerosis. Neurobiol Dis 2012, 48:124–131.
13. Nishioka K, Wider C, Vilariño-Güell C, Soto-Ortolaza AI, Lincoln SJ, Kachergus
JM, Jasinska-Myga B, Ross OA, Rajput A, Robinson CA, Ferman TJ, Wszolek ZK,
Dickson DW, Farrer MJ: Association of alpha-, beta-, and gamma-synuclein
with diffuse Lewy body disease. Arch Neurol 2010, 67(8):970–975.
14. Wersinger C, Sidhu A: Partial regulation of serotonin transporter function
by gamma-synuclein. Neurosci Lett 2009, 453(3):157–161.
15. Surgucheva I, Sharov VS, Surguchov A: γ-Synuclein: seeding of α-synuclein
aggregation and transmission between cells. Biochemistry 2012,
51(23):4743–4754.
16. Lema Tomé CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P:
Inflammation and α-synuclein’s prion-like behavior in Parkinson’s
disease–is there a link? Mol Neurobiol 2013, 47(2):561–574.
17. Olanow CW, Brundin P: Parkinson’s disease and alpha synuclein: is
Parkinson’s disease a prion-like disorder? Mov Disord 2013, 28(1):31–40.
18. Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW,
McGarvey NH, Ayers JI, Notterpek L, Borchelt DR, Golde TE, Giasson BI:
Intramuscular injection of α-synuclein induces CNS α-synuclein path-
ology and a rapid-onset motor phenotype in transgenic mice. Proc Natl
Acad Sci U S A 2014, 111(29):10732–10737.
19. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS,
Shen J, Takio K, Iwatsubo T: alpha-Synuclein is phosphorylated in
synucleinopathy lesions. Nat Cell Biol 2002, 4(2):160–164.
20. Oueslati A, Fournier M, Lashuel HA: Role of post-translational modifications
in modulating the structure, function and toxicity of alpha-synuclein:
implications for Parkinson’s disease pathogenesis and therapies. Prog Brain Res
2010, 183:115–145.
21. Braithwaite SP, Stock JB, Mouradian MM: α-Synuclein phosphorylation as a
therapeutic target in Parkinson’s disease. Rev Neurosci 2012, 23(2):191–198.
22. Vicente Miranda H, Xiang W, de Oliveira RM, Simões T, Pimentel J, Klucken J,
Penque D, Outeiro TF: Heat-mediated enrichment of α-synuclein from cells
and tissue for assessing post-translational modifications. J Neurochem 2013,
126(5):673–684.
23. Kokoulina P, Rohn TT: Caspase-cleaved transactivation response DNA-
binding protein 43 in Parkinson’s disease and dementia with Lewy bodies.
Neurodegener Dis 2010, 7(4):243–250.
24. Halliday GM, Stevens CH: Glia: initiators and progressors of pathology in
Parkinson’s disease. Mov Disord 2011, 26(1):6–17.
25. Sacino AN1, Thomas MA, Ceballos-Diaz C, Cruz PE, Rosario AM, Lewis J, Giasson
BI, Golde TE: Conformational templating of α-synuclein aggregates in
neuronal-glial cultures. Mol Neurodegener 2013, 8:17. doi:10.1186/1750-1326-8-17.
Surgucheva et al. Acta Neuropathologica Communications 2014, 2:132 Page 9 of 9
http://www.actaneurocomms.org/content/2/1/13226. Sosunov AA, Guilfoyle E, Wu X, McKhann GM 2nd, Goldman JE: Phenotypic
conversions of “protoplasmic” to “reactive” astrocytes in Alexander
disease. J Neurosci 2013, 33(17):7439–7450.
27. Sosunov AA, Wu X, Tsankova NM, Guilfoyle E, McKhann GM 2nd, Goldman JE:
Phenotypic heterogeneity and plasticity of isocortical and hippocampal
astrocytes in the human brain. J Neurosci 2014, 34(6):2285–2298.
28. Braak H, Sastre M, Del Tredici K: Development of alpha-synuclein
immunoreac-tive astrocytes in the forebrain parallels stages of
intraneuronal pathology in sporadic Parkinson’s disease. Acta Neuropathol
2007, 114:231–241.
29. Kovacs GG, Breydo L, Green R, Kis V, Puska G, Lőrincz P, Perju-Dumbrava L,
Giera R, Pirker W, Lutz M, Lachmann I, Budka H, Uversky VN, Molnár K, László L:
Intracellular processing of disease-associated α-synuclein in the human
brain suggests prion-like cell-to-cell spread. Neurobiol Dis 2014, 69:76–92.
30. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer
B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E: Mechanisms of
hybrid oligomer formation in the pathogenesis of combined Alzheimer’s
and Parkinson’s diseases. PLoS One 2008, 3:e3135. doi:10.1371/journal.
pone.0003135.
31. Forman MS, Schmidt ML, Kasturi S, Perl DP, Lee VM, Trojanowski JQ: Tau
and alpha-synuclein pathology in amygdala of Parkinsonism-dementia
complex patients of Guam. Am J Pathol 2002, 160(5):1725–1731.
32. Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Goncalves SA, Pera M,
Suarez-Calvet M, Clarimon J, Outeiro TF, Lleó A: Tau enhances alpha-synuclein
aggregation and toxicity in cellular models of synucleinopathy. PLoS One
2011, 6(10):e26609.
33. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM: Synergistic
interactions between Abeta, tau, and alpha-synuclein: acceleration of
neuropathology and cognitive decline. J Neurosci 2010, 30(21):7281–7289.
34. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M,
Mucke L: Beta-amyloid peptides enhance alpha-synuclein accumulation and
neuronal deficits in a transgenic mouse model linking Alzheimer’s disease
and Parkinson’s disease. Proc Natl Acad Sci U S A 2001, 98(21):12245–12250.
35. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT,
Trojanowski JQ, Lee VM: Initiation and synergistic fibrillization of tau and
alpha-synuclein. Science 2003, 300:636–640.
36. Mukaetova-Ladinska EB, Milne J, Andras A, Abdel-All Z, Cerejeira J, Greally E,
Robson J, Jaros E, Perry R, McKeith IG, Brayne C, Xuereb J, Cleghorn A,
Doherty J, McIntosh G, Milton I: Alpha- and gamma-synuclein proteins are
present in cerebrospinal fluid and are increased in aged subjects with
neurodegenerative and vascular changes. Dement Geriatr Cogn Disord
2008, 26(1):32–42. doi:10.1159/000141039.
37. Surguchov A: Synucleins: are they two-edged swords? J Neurosci Res 2013,
91(2):161–166.
doi:10.1186/s40478-014-0132-8
Cite this article as: Surgucheva et al.: New α- and γ-synuclein
immunopathological lesions in human brain. Acta Neuropathologica
Communications 2014 2:132.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
